Methods of treating, reducing, or preventing autoimmune...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S023100, C536S024300, C536S024330, C536S024500

Reexamination Certificate

active

07973016

ABSTRACT:
The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of TLR-9 for the identification of novel therapeutics for autoimmune conditions.

REFERENCES:
patent: 5675060 (1997-10-01), Benoist et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 6653292 (2003-11-01), Krieg et al.
patent: 7208478 (2007-04-01), Carson et al.
patent: 7271156 (2007-09-01), Krieg et al.
patent: WO 00/09159 (2000-02-01), None
patent: WO 00/64469 (2000-11-01), None
Wu et al. (Journal of Experimental Medicine, 2007 vol. 204, No. 8, published Jul. 23, 2007, pp. 1911-1922).
Ballas et al., “Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs,”J. Immunol. 167:4878-4886 (2001).
Chiang et al., “Ribavirin or CpG DNA Sequence-Modulated Dendritic Cells Decrease the IgE Level and Airway Inflammation,”Am. J. Respir. Crit. Care Med. 168:575-580 (2003).
Choe et al., “Interleukin 1 Receptor Dependence of Serum Transferred Arthritis Can be Circumvented by Toll-Like Receptor 4 Signaling,”J. Exp. Med. 197:537-542 (2003).
Daniliuc et al., “Hypoxia Inactivates Inducible Nitric Oxide Synthase in Mouse Macrophages by Disrupting its Interaction with Alpha-Actinin 4,”J. Immunol. 171:3225-3232 (2003).
Deng and Tarkowski, “Synovial Cytokine mRNA Expression During Arthritis Triggered by CpG Motifs of Bacterial DNA,”Arthritis Res. 3:48-53 (2001).
Deng et al., “Intra-Articularly Localized bacterial DNA containing CpG Motifs Induces Arthritis,”Nat. Med. 5:702-705 (1999).
Gramzinski et al., “Interleukin-12- and Gamma Interferon-Dependent Protection Against Malaria Conferred by CpG Oligodeoxynucleotide in Mice,”Infect. Immun. 69:1643-1649 (2001).
Hartung et al., “Th2-Mediated Atopic Disease Protection in Th1-Mediated Rheumatoid Arthritis,”Clin. Exp. Rheumatol. 21:481-484 (2003).
Ji et al., “Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-Induced Arthritis,”J. Exp. Med. 196:77-85 (2002).
Ji et al., “Genetic Influences on the End-Stage Effector Phase of Arthritis,”J. Exp. Med. 194:321-330 (2001).
Korganow et al., “From Systemic T Cell Self-Reactivity to Organ-Specific Autoimmune Disease Via Immunoglobulins,”Immunity10:451-461 (1999).
Kouskoff et al., “Organ-Specific Disease Provoked by Systemic Autoimmunity ,”Cell87:811-822 (1996).
Krieg, “CpG Motifs in Bacterial DNA and Their Immune Effects,”Annu. Rev. Immunol. 20:709-760 (2002).
Shirota et al., “B Cells Capturing Antigen Conjugated with CpG Oligodeoxynucleotides Induce Th1 Cells by Elaborating IL-12,”J. Immunol. 169:787-794 (2002).
International Search Report for PCT/US2005/02097 dated Jun. 9, 2006.
International Preliminary Report on Patentability for PCT/US2005/02097 dated Aug. 29, 2006.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treating, reducing, or preventing autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating, reducing, or preventing autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating, reducing, or preventing autoimmune... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2689628

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.